Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoronaVac Booster in Adults Previously Vaccinated with Inactivated COVID-19 Vaccines
NCT05165732Phase 4Suspended
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Geometric Mean Titer of neutralizing antibodies, Seroconversion rate of neutralizing antibodies and 1 more. Started Dec 2022; status: suspended.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05165732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165732.